| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01720270 |
| P698 | PubMed publication ID | 2180498 |
| P2093 | author name string | W Hiddemann | |
| T Büchner | |||
| P2860 | cites work | [Autologous bone marrow transplantation] | Q72572819 |
| Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings | Q72664721 | ||
| Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients | Q33426381 | ||
| A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. | Q33432075 | ||
| Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study | Q33447912 | ||
| Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study. | Q33452126 | ||
| 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia | Q33475015 | ||
| Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. | Q33482844 | ||
| Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. | Q33483037 | ||
| High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia | Q34180181 | ||
| Autotransplants in leukaemia | Q38359403 | ||
| High dose therapy and autologous bone marrow transplant (ABMT) in acute leukemia: is purging necessary? | Q38624735 | ||
| 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia | Q39394250 | ||
| Autologous bone marrow transplantation in acute leukaemia | Q39528257 | ||
| The nature of remission in acute myeloblastic leukaemia | Q39568198 | ||
| Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review | Q39675239 | ||
| A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes | Q39749269 | ||
| Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies | Q39759760 | ||
| Acute lymphoblastic leukemia: Treatment | Q39770571 | ||
| Advances in the Treatment of Acute Myelogenous Leukemia | Q39791590 | ||
| Podophyllotoxin derivative VP 16-213 | Q39825232 | ||
| Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy | Q39992397 | ||
| Control of normal cell differentiation in leukemia | Q40662266 | ||
| Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen | Q40788557 | ||
| Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia | Q40805621 | ||
| High dose cytosine arabinoside in the management of refractory acute leukaemia. | Q40843081 | ||
| Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia | Q41248110 | ||
| The characteristics and outcome of patients with late relapse acute myelogenous leukemia | Q41287453 | ||
| Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia | Q41879185 | ||
| Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia | Q41971394 | ||
| High-dose cytosine arabinoside therapy for refractory leukemia | Q42244165 | ||
| High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia | Q43723899 | ||
| Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML). | Q44014284 | ||
| High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia | Q44016119 | ||
| Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial | Q44029830 | ||
| Genetic instability in the development of drug resistance | Q44172655 | ||
| High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. | Q46017829 | ||
| Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f | Q52866344 | ||
| High-dose cytosine arabinoside for acute nonlymphocytic leukemia. | Q53725892 | ||
| Response to salvage therapy and survival after relapse in acute myelogenous leukemia. | Q54348128 | ||
| Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia. | Q54368670 | ||
| Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. | Q54389072 | ||
| The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. | Q54399527 | ||
| Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia. | Q54400913 | ||
| Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. | Q54413132 | ||
| Is maintenance therapy necessary for acute lymphoblastic leukaemia? | Q54423949 | ||
| Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. | Q54430373 | ||
| Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia. | Q54431987 | ||
| Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. | Q54433485 | ||
| [AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia]. | Q54449337 | ||
| High-dose cytosine arabinoside in the treatment of resistant acute leukemia. | Q54449519 | ||
| 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study. | Q54452643 | ||
| Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. | Q54460024 | ||
| Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside. | Q54469307 | ||
| [Phase II study of AMSA in adults with acute therapy-refractory leukemias]. | Q54493562 | ||
| Evidence for differentiation of human leukemic blood cells in diffusion chamber culture | Q67561986 | ||
| Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia | Q67920104 | ||
| Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia | Q68748553 | ||
| Prognostic factors in adult patients with acute leukemia at first relapse | Q68753790 | ||
| A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin | Q68771168 | ||
| Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease | Q68772893 | ||
| Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse | Q68772897 | ||
| Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia | Q68772963 | ||
| Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide | Q68885727 | ||
| Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study | Q68996902 | ||
| Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia | Q69157759 | ||
| Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci | Q69368203 | ||
| Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia | Q69428697 | ||
| Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine | Q69481480 | ||
| Allogeneic marrow transplantation for acute non-lymphoblastic leukemia: first remission versus after first relapse | Q69499305 | ||
| Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia | Q69506139 | ||
| Growth response of residual leukemia after initial drug therapy | Q69565978 | ||
| Treatment of acute leukemia with amsacrine and high-dose cytarabine | Q69803853 | ||
| Amsacrine with high-dose cytarabine in acute leukemia | Q69805989 | ||
| Phase I-II trial of mitoxantrone in acute leukemia | Q69832560 | ||
| Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia | Q69833062 | ||
| Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias | Q69844848 | ||
| Mitozantrone and high-dose cytarabine in adult acute myeloid leukaemia | Q69864839 | ||
| Mitoxantrone in the treatment of relapsed and refractory acute leukemia | Q69901554 | ||
| Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group | Q69918667 | ||
| Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation | Q69919310 | ||
| Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia | Q69937076 | ||
| Comparison of results of salvage therapy in adult acute myelogenous leukemia | Q70375900 | ||
| Mitoxantrone in relapsed and refractory acute leukemia | Q70385121 | ||
| Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma | Q70595564 | ||
| Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group | Q70920685 | ||
| Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia | Q70922197 | ||
| Phase II study of amsacrine gluconate in refractory leukemia | Q70923305 | ||
| Prediction of complete remission in patients with refractory acute leukemia treated with AMSA | Q70930304 | ||
| A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study | Q70965524 | ||
| Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system | Q71186764 | ||
| High-dose cytosine arabinoside: clinical response to therapy in acute leukemia | Q71478505 | ||
| Phase II trial of mitoxantrone in refractory acute leukemia | Q71733423 | ||
| Mitoxantrone in patients with acute leukemia in relapse | Q71761218 | ||
| A phase II study of aclacinomycin A in acute leukemia in adults | Q72001407 | ||
| The heritable nature of clonal characteristics in acute myeloblastic leukemia | Q72007680 | ||
| Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults | Q72042575 | ||
| Remission induction in acute myeloid leukaemia with oral etoposide | Q72540199 | ||
| P433 | issue | 3 | |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 163-171 | |
| P577 | publication date | 1990-03-01 | |
| P1433 | published in | Blut | Q27709414 |
| P1476 | title | Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment | |
| P478 | volume | 60 |
| Q33769677 | Autologous bone marrow transplantation in acute leukemia |
| Q43622754 | Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial |
| Q53915843 | Correlation between cyclin A gene expression in adult patients with acute leukemia and drug resistance |
| Q37717088 | Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens |
| Q46796796 | High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia |
| Q40567141 | Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission |
| Q74171245 | Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483) |
| Q38569175 | Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. |
| Q67479583 | Mitoxantrone and intermediate‐dose cytosine arabinoside for poor‐risk acute leukemias: Response to treatment and factors influencing outcome |
| Q70496901 | Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia |
| Q38140944 | Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy |
Search more.